PATHFAST®
Analyzer

The PATH to better
cardiac care starts here

When every minute matters

Trust the first point-of-care (POC) high-sensitivity cardiac troponin (hs-cTn) assay in the U.S.

Laboratory excellence, propelling ED performance

The PATHFAST Analyzer accelerates urgent cardiac care decisions in the Emergency Department (ED) with reliable, lab-quality testing at the point of care.

PATHFAST meets lab standards for quality, consistency, & efficiency

PATHFAST provides highly accurate, lab-quality results from whole blood samples using a combination of chemiluminescence and proprietary Magtration® technology.

  • Results unaffected by hemolysis
  • Easily interfaces with Laboratory Information Systems (LIS)

PATHFAST meets ED goals of accuracy, efficiency & flexibility

pathfast-icon-throughput.webp
pathfast-icon-beaker.webp
pathfast-icon-box.webp
pathfast-icon-thumb.webp

Results available

in under 17 minutes

Flexibility to run

up to 6 tests at once

Space-saving benchtop

design for the ED

or STAT lab

User-friendly

operation

Eliminating preanalytical delays associated with core-laboratory testing has been shown to:

Accelerate care decisions by 40 minutes1

Reduce length of stay by 34 minutes1

When every minute matters
Trust the first POC hs-cTn assay in the U.S.

PATHFAST hs-cTnI-II

With PATHFAST, EDs can access an optimal solution to accelerate the assessment and disposition of patients with suspected acute coronary syndrome (ACS).

hs-cTn is the preferred assay for aiding in the diagnosis of acute myocardial infarction (AMI).2

Lab-quality results

  • 6% CV at the 99th percentile cutoff of 29 ng/L3
  • 4.1 ng/L limit of quantitation (LoQ, I.e. functional sensitivity)3

When and where you need them

  • Results in 17 minutes within care pathway
  • Run up to 6 tests at once

Optimizing ED performance

  • Proven performance in 0/1, 0/2, and 0/3 h accelerated diagnostic protocols4–6

Access to quicker test results can help clinicians identify urgent cardiac concerns sooner, reduce length of stay, and improve patient satisfaction.

Discover more resources

Visit the online resource center for additional education and support materials.

NT-proBNP is used to aid in the diagnosis of patients with suspected congestive acute heart failure (CHF). Rapid results at the point of care inform rapid risk stratification and admission decisions.

More accurate diagnosis and improved risk stratification for patients with acute dyspnea7

Strongest independent predictor of a final diagnosis of acute CHF8

NT-proBNP plus clinical judgment is superior to either alone8

Discover the best of both worlds

hs-cTn-II + NT-proBNP

PATHFAST is the only point-of-care system to offer both hs-cTnI-II and NT-proBNP, two gold-standard cardiac biomarker tests, on a single platform.

A complete menu of urgent STAT tests

PATHFAST facilitates decisions for a range of assays including:

hs-cTnI-II

cTnI-II

D-Dimer

CK-MB

NT-proBNP

hs-CRP

Myoglobin

Proactive support
every step of the way

Polymedco is committed to being one of the easiest companies to do business within healthcare. We work closely with laboratorians, clinicians, and administrators to maximize the value of our tests in every ED.

Learn more about the dedicated support you can expect from a PATHFAST partnership

Technical specifications

Instrument type

Benchtop Analyzer

Throughput

Up to 6 samples or assays per run

Measuring time

<17 minutes for to up to 6 simultaneous samples

Sampling material

Whole blood, plasma

Measuring principle

Chemiluminescence enzyme immunoassay technology (CLEIA) combined with proprietary Magtration® technology

Reaction temperature

37.5° C

Sample volume

100 µL

Wavelength

300 – 650 nm

Data storage

Patient data: 1000

QC data

1800

CAL data

300

Data transfer

ASTM standard

Dimensions

13.5 in. W x 22.4 in. D x 18.7 in. H

Weight

62 lbs

Electrical requirements

100 – 240 Vac

Monitor/keyboard

LCD Touchscreen

Printer/PC

Integrated

Interface

RS-232C

Calibration

Factory calibration, 2-point calibration every 4 weeks

24-h operation (standby)

Ordering information

Learn more about the dedicated
support you can expect from
a PATHFAST partnership

Contact Polymedco
  1. Goyder C, Tan PS, Verbakel J, et al. Impact of point-of-care panel tests in ambulatory care: a systematic review and meta-analysis. BMJ Open. 2020;10(2):e032132. doi:10.1136/bmjopen-2019-032132
  2. Kontos, M, de Lemos, J. et al. 2022 ACC Expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(20):1925-1960. doi:10.1016/j.jacc.2022.08.750
  3. Point of care cardiac troponin I and T assay analytical characteristics. IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Accessed March 13, 2024. https://ifcc.org/ifcc-education-division/emd-committees/committee-on-clinical-applications-of-cardiac-bio-markers-c-cb/biomarkers-reference-tables/
  4. Sörensen NA, Neumann JT, Ojeda F, et al. Diagnostic evaluation of a high-sensitivity troponin I point-of-care assay. Clin Chem. 2019;65(12):1592-1601. doi:10.1373/clinchem.2019.307405
  5. Koechlin L, Boeddinghaus J, Lopez-Ayala P, et al. External validation of the 0/1h-algorithm and derivation of a 0/2h-algorithm using a new point-of-care Hs-cTnI assay. Am Heart J. 2024;268:104-113. doi:10.1016/j.ahj.2023.11.014
  6. Lehmacher J, Sörensen NA, Twerenbold R, et al. Diagnostic and prognostic value of the sex-specific 99th percentile of four high-sensitivity cardiac troponin assays in patients with suspected myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2024;13(1):3-12.doi:10.1093/ehjacc/zuad131
  7. Bingisser R, Cairns CB, Christ M, et al. Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: Current status and future perspectives. Am Heart J. 2013;166(4). doi:10.1016/j.ahj.2013.06.012
  8. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the Emergency Department (Pride) study. Am J Cardiol. 2005;95(8):948-954. doi:10.1016/j.amjcard.2004.12.033